New malaria vaccine shows 87% efficacy in early human trial
A new malaria vaccine called PfSPZ-LARC2 prevented infection in 87% of vaccinated people in an early-stage human trial, Medical Xpress reported. Researchers at UW Medicine and partners exposed vaccinated and unvaccinated participants to malaria 12 to 16 weeks after vaccination. All seven people who received a placebo became infected, while only two of 15 vaccinated people developed the disease.
The vaccine uses a genetically modified version of the malaria parasite. All infected participants were safely treated, and the vaccine was well tolerated by those who received it, according to the report.
Researchers presented these findings at the annual meeting of the American Society of Tropical Medicine and Hygiene. The trial, which began enrolling participants in summer 2025, was led by Dr. Sean Murphy at the University of Washington School of Medicine and involved researchers from Fred Hutch Cancer Center and UW School of Medicine.
Malaria kills more than 600,000 people worldwide each year, according to Medical Xpress. Vaccines that completely prevent infection are needed, rather than just reducing symptom severity, researchers said.
What it means in Raleigh
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Trillium Health Resources, Vaya Partners (Vaya Health + Partners Health Management, merged 2026).
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.
